Global Cord Blood Corporation Announces Cellenkos Receives FDA Clearance for IND Application for CK0804 as an Add-on Therapy to Ruxolitinib for the Treatment of Myelofibrosis

0

HONG KONG, June 16, 2022 /PRNewswire/ — Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announcee that Cellenkos, Inc. (“CLNK”) recently announced that the U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug (“IND”) application to initiate an open-label Phase 1b study of CK0804 as add-on therapy to ruxolitinib in patients with myelofibrosis who show a suboptimal response to ruxolitinib. Details related to this news can be found via the following announcement from Cellenkos:

Cellenkos Receives Investigational New Drug Application (IND) FDA Clearance for CK0804 as an Add-on Therapy to Ruxolitinib for the Treatment of Myelofibrosis (prnewswire.com)

Ms. Ting Zheng, Chief Executive Officer and President of GCBC, said, “The Global Cord Blood Team is encouraged by the above news announced by CLNK, which highlights a potentially transformative treatment for patients with myelofibrosis. We congratulate the CLNK team for this development.

About Global Cord Blood Corporation

Global Cord Blood Corporation is an umbilical cord blood bank operator serving several regions of the China. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the company’s website at: http://www.globalcordbloodcorp.com.

For more information please contact:

World Cord Blood Society
Investor Relations Department
Tel: (+852) 3605-8180
E-mail: [email protected]

ICR, Inc.
William Zima
Tel: (+86) 10-6583-7511
Such. USA: (646) 405-5185
E-mail: [email protected]

SOURCE World Cord Blood Society

Share.

Comments are closed.